Matches in Nanopublications for { <http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#association> ?p ?o ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- association type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
- association label "Sertraline has shown efficacy and safety at doses of 50-200 mg/day [72] in treating phobic-related states, with a greater reduction in symptoms related to anxiety/fear, physical symptoms and avoidance behaviors [73]. Clinical improvements in obsessive symptoms and phobic behavior have been achieved with long-term therapy, with a good tolerability profile. A rapid sertraline titration up to 200 mg/day correlated with fast response rates. A 20-week study with sertraline 50-200 mg/day produced significant improvements both in functioning and social skills [74]. Stable sertraline treatment guaranteed lower recurrence rates, and a general improvement in quality of life. Placebo-controlled studies consistently showed sertraline-related treatment response [72, 75, 76], although with one exception [77]. Treatment of refractory OCD with high doses of sertraline (250-400 mg/day) resulted in a significant symptom improvement and a similar rate of adverse events observed with a 200 mg/day dose [78]." assertion.
- association object MONDO_0008114 assertion.
- association predicate treats assertion.
- association category ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
- association subject DB01104 assertion.
- association publications 30101713 assertion.
- association has_population_context context assertion.
- association relation NCIT_C94303 assertion.
- association aggregator_knowledge_source knowledge-collaboratory assertion.